CLOV Clover Health Investments, Corp. Under investigation
Free read

Clover Health Confirms PHI Breach, Member Notifications Still Pending

At edition (Jul 17, 2026) $2.3B · Live $2.3B

A threat actor used social engineering to access three Clover Health employee accounts on July 4, 2026, obtaining personally identifiable information and protected health information belonging to Medicare Advantage members. The company, which serves approximately 155,000 members, has not yet notified affected members or regulators, and the investigation remains open. Management asserts no material impact is anticipated, but the precise scope of compromised data has not been determined.

SPRY ARS Pharmaceuticals, Inc. Management crisis

ARS Pharmaceuticals Founder-CEO and CMO Both Terminated Within Nine Days

At edition (Jul 17, 2026) $741M · Live $741M

ARS Pharmaceuticals co-founder and CEO Richard Lowenthal was terminated without cause on July 6, 2026, and Chief Medical Officer Sarina Tanimoto, M.D. was terminated without cause nine days later on July 15 — the same date Lowenthal resigned his board seat as a condition of receiving severance. Both received additional one-time payments of $217,350 and $111,780, respectively, representing prorated 2026 target bonuses, conditioned on releases of claims. The departures leave incoming CEO Donn Casale — at the company since June 1 — steering a commercial-stage biotech with no CMO named, a major formulary decision pending, and Phase 2b trial data due in Q4 2026.

EYPT Eyepoint, Inc. Regulatory Oversight

EyePoint Settles False Claims Act Case, Accepts Five-Year Compliance Agreement

At edition (Jul 17, 2026) $1.1B · Live $1.1B

EyePoint, Inc. resolved allegations that its sales and marketing practices for eye-drop substitute DEXYCU® violated the False Claims Act, agreeing to pay $4,678,981.86 plus interest and $166,500 in relator's attorneys' fees to settle a whistleblower-driven civil action brought by the DOJ, OIG-HHS, and the TRICARE program. In parallel, a five-year Corporate Integrity Agreement with OIG-HHS took effect July 13, 2026, imposing board-level compliance oversight, an independent review organization, and mandatory employee screening. The settlement resolves a government investigation that had been flagged in EyePoint risk disclosures since at least August 2022, when the company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts.

LNN Lindsay, Corp. Management crisis

Lindsay CFO Resigns After Eight Months, No Successor Named

At edition (Jul 17, 2026) $1.2B · Live $1.2B

Sam Hinrichsen, who became Lindsay Corporation's CFO on January 1, 2026, has notified the Board of his intent to resign effective August 31, 2026 — less than eight months after taking the seat. The company cites personal reasons and explicitly denies any disagreements or accounting-related concerns, and has begun an executive search. The departure is the third senior-level exit at Lindsay in under a year, following the retirement of prior CFO Brian Ketcham and the departure of Irrigation President Gustavo Oberto, and arrives as revenues have declined year-over-year in each of the three quarters Hinrichsen oversaw.